Citius Oncology (CTOR) Assets Average (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Assets Average data on file, last reported at $105.3 million in Q1 2026.

• On a quarterly basis, Assets Average rose 15.8% year-over-year to $105.3 million in Q1 2026; TTM through Mar 2026 was $105.3 million, a 15.8% increase from a year earlier, with the FY2025 full-year figure at $92.7 million, up 18.04% from the prior year.
• Assets Average for Q1 2026 stood at $105.3 million, roughly flat from $105.5 million in the prior quarter.
• Over the last five years, Assets Average for CTOR reached as high as $105.5 million in Q4 2025 and fell as low as $48.9 million in Q2 2024.
• Historically, Assets Average has averaged $77.7 million across 4 years, with a median of $69.3 million in 2023.
• Across the five-year window, Assets Average fell 29.42% in 2024 and surged 87.13% in 2025, its largest moves.
• Year by year, Assets Average stood at $60.2 million in 2023, then surged by 45.27% to $87.4 million in 2024, then advanced by 20.63% to $105.5 million in 2025, then dropped by 0.12% to $105.3 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $105.3 million in Q1 2026, $105.5 million in Q4 2025, and $96.3 million in Q3 2025.